Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 426

The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.

Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review

Open access
Mayer, Kenneth H., Agwu, Allison, Malebranche, David·2020·Advances in Therapy

Abstract

Antiretroviral pre-exposure prophylaxis (PrEP) to prevent HIV transmission was first approved by the US Food and Drug Administration in 2012. Despite correlations of decreases in new HIV infections being greatest where PrEP has been deployed, the uptake of PrEP is lagging, particularly among populations with disproportionate HIV burden. This narrative review seeks to identify individual and systemic barriers to PrEP usage in the USA. A comprehensive search of recent literature uncovered a complex array of structural, social, clinical, and behavioral barriers, including knowledge/awareness of PrEP, perception of HIV risk, stigma from healthcare providers or family/partners/friends, distrust of healthcare providers/systems, access to PrEP, costs of PrEP, and concerns around PrEP side effects/medication interactions. Importantly, these barriers may have different effects on specific populations at risk. The full potential of PrEP for HIV prevention will not be realized until these issues are addressed. Strategies to achieve this goal should include educational interventions, innovative approaches to delivery of HIV care, financial support, and destigmatization of PrEP and PrEP users. Until then, PrEP uptake will continue to be suboptimal, particularly among those who need it most. Pre-exposure prophylaxis (PrEP) is a way of preventing HIV. By taking a daily pill, which contains two medicines, HIV can be stopped before it causes an infection. PrEP is prescribed for people at risk of HIV infection. However, many people who are at risk do not use PrEP. We explored the reasons for this. We found that many individuals at risk had not heard of PrEP, so would be unable to ask their doctors for it. Even among healthcare providers themselves, some were not aware of PrEP or how it should be used. For individuals who have heard of PrEP, unfortunately a stigma remains around HIV that deters some people from seeking the treatment. Furthermore, many individuals at risk have experienced bias at the hands of healthcare providers, deepening distrust of the medical establishment. Many individuals at risk also experience poverty and although there are multiple financial assistance options for PrEP, these can be difficult to access without support. Public education and training of healthcare providers may address many of the barriers we found, but deep-rooted issues such as racism and bias will require significant changes within the healthcare system.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s12325-020-01295-0

Cites

124 of 124 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 124 references

Metadata

Authors
Mayer, K. H., Agwu, A., & Malebranche, D.
Venue
Advances in Therapy
Published
2020-03-30
Volume
37
Issue
5
Pages
1778-1811
ISSN
  • 0741-238X (ISSN-L)
  • 1865-8652
OpenAlex
W3013272485
Cited by
426
References
124
FWCI
2.59
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review. https://app.cochat.ai/papers/10.1007/s12325-020-01295-0
The paper
Mayer, K. H., Agwu, A., & Malebranche, D. (2020). Barriers to the Wider Use of Pre-exposure Prophylaxis in the United States: A Narrative Review. Advances in Therapy. https://doi.org/10.1007/s12325-020-01295-0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.